Cooperate to Achieve Mutual Benefits and Complementary Advantages——Xiamen University and Cosunter Pharmaceutical Co., Ltd. Signed Strategic Cooperation Agreement
The 2018 working conference on the school and region strategic cooperation between Xiamen University and nine cities and one area of Fujian Province themed “Seek cooperation for mutual development and make something excellent” was held in Xiamen University.
The First Meeting of the First Academic Committee of Cosunter’s Key Laboratory for Research of Drugs
Recently, the first meeting of the first Academic Committee of Cosunter’s Key Laboratory for Research of Drugs for Liver Diseases in Fujian was convened successfully in Fuzhou.
Fujian Cosunter Pharmaceutical Co., Ltd. Won the Title of “National Intellectual Property Demonstration Enterprise”
The State Intellectual Property Office published the List of National Intellectual Property Demonstration Enterprises and Advantage Enterprises in 2017 and Fujian Cosunter Pharmaceutical Co., Ltd. was among the list, winning the honorary title of “National Intellectual Property Demonstration Enterprise”.
The Adefovir Dipivoxil Patent of Fujian Cosunter Pharmaceutical Co., Ltd. Is Granted China Patent Recognition Award
China Patent Recognition Award was granted to the patented invention of “M-crystal form of adefovir dipivoxil and its preparation method and application in drugs” developed by Fujian Cosunter Pharmaceutical Co., Ltd.
Fujian Cosunter Pharmaceutical Co., Ltd. Obtains Approval for Setup of Academician Expert Workstation
The Academician Expert Workstation of Fujian Cosunter Pharmaceutical Co., Ltd. has been honored with the title"Fujian Provincial Academician Expert Workstation",becoming one of the 23 newly established provincial academician expert workstations across Fujian.
Disclosure of Cosunter’s Environmental Influence Assessment Report for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project.
Strategic Cooperation Agreement signed by Cosunter and Sinopharm Group
Both parties hope to share all strategic resources by intercommunication on the basis of separated purchasing negotiated and relying on third-party logistics and multiple-warehouse operation for the win-win purpose.
Clinical Data Collected over Three Years from TDF-ETV Non-inferiority Control Trial by Cosunter First Released Globally at APASL Annual Meeting 2017
The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) was held at Shanghai International Convention Center on February 15 - 19, 2017 in Shanghai, China.
Strategic Cooperation Framework Agreement Signed by Cosunter and WuXi AppTec for “the Best Plan of HBV Treatment”
Cosunter cooperated with WuXi AppTec regarding the project related to HBV treatment method independently developed by Cosunter for the purpose of “the Best Plan of HBV Treatment”. The Strategic Cooperation Framework Agreement was signed by both parties on February 9, 2017.
Second Disclosure of Cosunter’s Environmental Influence Assessment for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project (simplified edition). We disclose the preliminary conclusion of this EIA for the project to the public according to the Law of the People's Republic of China on Appraising of Environment and the Temporary Methods of Public Consultation for EIA.